CTSO

SEC source: 0001104659-22-090254 · tm2223355-5_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,384

F7 · shares: These shares represent RSUs that will vest upon a "Change in Control" of the Company as defined in the Plan.

SEC source: 0001104659-22-090252 · tm2223355-4_4seq1.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-08-10

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest only upon the achievement of certain milestones before December 31, 2025. Specifically, (i) 70,000 options will vest if the Company obtains U.S. Food and Drug Administration approval for its product DrugSorb, (ii) 50,000 options will vest if the Company achieves $80 million or more in annual ex-U.S. sales, (iii) 100,000 options will vest if the Company achieves $20 million or more in annual U.S. sales, and (iv) 30,000 options will vest if the Company achieves U.S. GAAP breakeven.

SEC source: 0001104659-22-090252 · tm2223355-4_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,000

Underlying: Common Stock · 86,000 shares

Expires 2032-08-10

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090252 · tm2223355-4_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 512,545

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes (a) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 10,100 RSUs granted on March 15, 2018, (ii) 17,900 RSUs granted on February 24, 2017, (iii) 54,000 RSUs granted on June 7, 2016 and (iv) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (i) 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof and (ii) 69,000 RSUs granted on August 10, 2022 reported on this Form 4 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 215,806 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-22-090247 · tm2223355-3_4seq1.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,000

Underlying: Common Stock · 215,000 shares

Expires 2032-08-10

F7 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest only upon the achievement of certain milestones before December 31, 2025. Specifically, (i) 45,000 options will vest if the Company obtains U.S. Food and Drug Administration approval for its product DrugSorb, (ii) 45,000 options will vest if the Company achieves $80 million or more in annual ex-U.S. sales, (iii) 50,000 options will vest if the Company achieves $20 million or more in annual U.S. sales, and (iv) 75,000 options will vest if the Company achieves U.S. GAAP breakeven.

SEC source: 0001104659-22-090247 · tm2223355-3_4seq1.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-08-10

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090247 · tm2223355-3_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,161

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: (a) 16,484 RSUs granted on April 12, 2021 and unvested as of the date hereof and (b) 55,500 RSUs granted on August 10, 2022 reported on this Form 4 and unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (iii) 151,677 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-22-073622 · tm2219169-1_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 443,545

F1 · kind: The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a 10b5-1 trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 10,100 RSUs granted on March 15, 2018, (ii) 17,900 RSUs granted on February 24, 2017, (iii) 54,000 RSUs granted on June 7, 2016 and (iv) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 215,806 shares of Common Stock owned by the reporting person, inclusive of the 2,000 shares purchased on June 21, 2022 and reported on this Form 4.

SEC source: 0001104659-22-072985 · tm2218917-2_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,545

F1 · kind: The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a 10b5-1 trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 213,806 shares of Common Stock owned by the reporting person, inclusive of the 3,000 shares purchased on June 16, 2022 and reported on this Form 4.

SEC source: 0001104659-22-072979 · tm2218917-1_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 768,351

F1 · kind: The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 528,351 shares of the Issuer's common stock owned by the reporting person, inclusive of the 2,221 shares of the Issuer's common stock reported on this Form 4.

SEC source: 0001104659-22-070156 · tm2218190d1_4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 766,130

F1 · kind: Reflects open market purchases made by the reporting person on June 9, 2022. Purchase price reflects the average price of purchases made in multiple transactions at prices ranging from $2.15 to $2.18, inclusive. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F1 · price: Reflects open market purchases made by the reporting person on June 9, 2022. Purchase price reflects the average price of purchases made in multiple transactions at prices ranging from $2.15 to $2.18, inclusive. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 526,130 shares of the Issuer's common stock owned by the reporting person, inclusive of the 16,000 shares of the Issuer's common stock reported on this Form 4.

SEC source: 0001104659-22-068656 · tm2217836-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 33,700

F1 · ownership.nature: Includes (i) 10,000 shares held by the Reporting Person's husband in a 401(k) account, (ii) 15,000 shares held by the Reporting Person's husband in an IRA account and (iii) 8,700 shares held by the Reporting Person's husband in a ROTH IRA account and reported on this Form 4. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-22-064664 · tm2216877-1_4seq1.xml · nonDerivative · entry 3

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 438,545

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F2 · balance_after: (continued from footnote 1) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof; and

F3 · balance_after: (continued from footnote 2) (iii) 210,806 shares of Common Stock owned by the reporting person, inclusive of the shares purchased on May 23, 2022 and reported on this Form 4.

SEC source: 0001104659-22-064664 · tm2216877-1_4seq1.xml · nonDerivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,418

SEC source: 0001104659-22-064664 · tm2216877-1_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,119

SEC source: 0001104659-22-062697 · tm2216006-1_4seq1.xml · nonDerivative · entry 6

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,800

F1 · balance_after: Includes (a) the following restricted stock units which will vest upon a "Change of Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, and (iii) 60,000 restricted stock units granted on June 7, 2017, and (b) 15,500 shares of common stock owned by the reporting person, inclusive of 11,000 total shares of common stock purchased on May 18, 2022 and reported on this Form 4.

SEC source: 0001104659-22-062697 · tm2216006-1_4seq1.xml · nonDerivative · entry 5

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,800

SEC source: 0001104659-22-062697 · tm2216006-1_4seq1.xml · nonDerivative · entry 4

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,800

SEC source: 0001104659-22-062697 · tm2216006-1_4seq1.xml · nonDerivative · entry 3

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,800

SEC source: 0001104659-22-062697 · tm2216006-1_4seq1.xml · nonDerivative · entry 2

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,800

SEC source: 0001104659-22-062697 · tm2216006-1_4seq1.xml · nonDerivative · entry 1

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,800

SEC source: 0001104659-22-061986 · tm2215854d1_4seq1.xml · nonDerivative · entry 1

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,315

SEC source: 0001104659-22-059474 · tm2215403d1_4seq1.xml · nonDerivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,300

F1 · balance_after: Includes (i) the following restricted stock units that will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 restricted stock units granted on March 15, 2018, (b) 6,000 restricted stock units granted on February 24, 2017, (c) 5,000 restricted stock units granted on June 7, 2016, and (d) 55,000 restricted stock units granted on April 8, 2015 and (ii) 10,000 shares of common stock purchased by the reporting person on May 11, 2022 and reported on this Form 4.

SEC source: 0001104659-22-059474 · tm2215403d1_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,500

SEC source: 0001104659-22-057514 · tm2214932-1_4.xml · nonDerivative · entry 1

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,046

F1 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 60,746 shares of common stock owned by the reporting person, inclusive of the 5,000 shares of common stock purchased in the open market and reported on this Form 4.

SEC source: 0001104659-22-042913 · tm2211684-2_4seq1.xml · derivative · entry 2

Kim Jiny · CIK 0001920967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,250

Underlying: Common Stock · 17,250 shares

Expires 2032-04-05

F2 · derivative.exercise_date: Reflects the grant of a stock option to purchase 17,250 shares of the Issuer's common stock, which will vest in four quarterly installments from the date of grant and becoming fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service on the applicable vesting date.

SEC source: 0001104659-22-042913 · tm2211684-2_4seq1.xml · nonDerivative · entry 1

Kim Jiny · CIK 0001920967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,300

F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

SEC source: 0001104659-22-023820 · tm226775d1_4.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Bernard Sobel Revocable Trust

Disclosed balance after: 2,000

F1 · ownership.nature: These shares are held in the Bernard Sobel Revocable Trust (the "Trust'"). On February 14, 2022, the reporting person became a trustee of the Trust. The reporting person is also a named beneficiary of the Trust. Accordingly, the reporting person may be deemed the beneficial owner of the shares held in the Trust.

SEC source: 0001104659-22-000566 · tm221390-1_4seq1.xml · nonDerivative · entry 3

Chan Phillip P. · CIK 0001442786 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 768,443

F1 · kind: The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted on December 9, 2021 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015.

F3 · balance_after: Includes the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: (a) 48,000 RSUs granted on April 12, 2021 and unvested on the date hereof, and (b) 20,000 RSUs granted on February 28, 2020 and unvested on the date hereof, and

F4 · balance_after: Includes 484,443 shares of the Issuer's common stock owned by the reporting person, inclusive of the 15,000 shares of the Issuer's common stock reported on this Form 4.

SEC source: 0001104659-22-000566 · tm221390-1_4seq1.xml · nonDerivative · entry 2

Chan Phillip P. · CIK 0001442786 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 762,981

F1 · kind: The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted on December 9, 2021 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001104659-22-000566 · tm221390-1_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 753,543

F1 · kind: The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted on December 9, 2021 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

SEC source: 0001104659-21-148900 · tm2135232-1_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 753,443

F1 · balance_after: Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015; (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: (a) 48,000 RSUs granted on April 12, 2021 and unvested on the date hereof, and (b) 20,000 RSUs granted on February 28, 2020 and unvested on the date hereof, and

F2 · balance_after: (iii) 469,443 shares of the Issuer's common stock owned by the reporting person, inclusive of the 5,000 shares of the Issuer's common stock reported on this Form 4.

SEC source: 0001104659-21-149251 · tm2135306-1_4seq1.xml · derivative · entry 3

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires 2022-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-149251 · tm2135306-1_4seq1.xml · nonDerivative · entry 2

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,639

SEC source: 0001104659-21-149251 · tm2135306-1_4seq1.xml · nonDerivative · entry 1

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-144035 · tm2134006-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 25,000

F1 · ownership.nature: Includes (i) 10,000 shares held by the Reporting Person's husband in a 401(k) account and (ii) 15,000 shares held by the Reporting Person's husband in an IRA account (including the 4,000 shares reported on this Form 4). The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-21-112499 · tm2126875-1_4seq1.xml · derivative · entry 3

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires 2022-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-112499 · tm2126875-1_4seq1.xml · nonDerivative · entry 2

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,046

F1 · price: Reflects the weighted average price of sales on August 31, 2021. The shares were sold in multiple transactions at prices ranging from $9.38 to $9.409, inclusive. The reporting person undertakes to provide to CytoSorbents Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person.

SEC source: 0001104659-21-112499 · tm2126875-1_4seq1.xml · nonDerivative · entry 1

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,046

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-050402 · tm2113016d8_4.xml · derivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,250

Underlying: Common Stock · 17,250 shares

Expires 2031-04-12

F1 · derivative.exercise_date: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options will vest in four equal parts on 4/12/2021, 6/30/2021, 9/30/2021 and 12/31/2021, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050401 · tm2113016d7_4.xml · derivative · entry 1

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,500

Underlying: Common Stock · 34,500 shares

Expires 2031-04-12

F1 · derivative.exercise_date: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options will vest in four equal parts on 4/12/2021, 6/30/2021, 9/30/2021 and 12/31/2021, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050400 · tm2113016d6_4.xml · derivative · entry 1

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,250

Underlying: Common Stock · 17,250 shares

Expires 2031-04-12

F1 · derivative.exercise_date: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options will vest in four equal parts on 4/12/2021, 6/30/2021, 9/30/2021 and 12/31/2021, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050399 · tm2113016d5_4.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,250

Underlying: Common Stock · 63,250 shares

Expires 2031-04-12

F4 · derivative.exercise_date: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050399 · tm2113016d5_4.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,000

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes: (i) 120,000 RSUs granted on April 9, 2020 that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan;

F3 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 40,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof; and (iii) 3,000 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-21-050398 · tm2113016d4_4.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock · 96,000 shares

Expires 2031-04-12

F4 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050398 · tm2113016d4_4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 769,339

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 72,000 RSUs granted on April 12, 2021 and unvested on the date hereof, (b) 20,000 RSUs granted on February 28, 2020 and unvested on the date hereof, and (c) 20,000 RSUs granted on July 22, 2019 and unvested on the date hereof; and (iii) 441,339 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-21-050397 · tm2113016d3_4.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,200

Underlying: Common Stock · 78,200 shares

Expires 2031-04-12

F4 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050397 · tm2113016d3_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 467,756

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 62,215 RSUs granted on April 12, 2021 and unvested on the date hereof; (b) 18,034 RSUs granted on February 28, 2020 and unvested on the date hereof; and (c) 18,034 RSUs granted on July 22, 2019 and unvested on the date hereof; and (iii) 162,473 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-21-050387 · tm2113016d2_4.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2031-04-12

F5 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050387 · tm2113016d2_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,372

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F3 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: (a) 49,450 RSUs granted on April 12, 2021 and unvested as of the date hereof, (b) 14,334 RSUs granted on February 28, 2020 and unvested as of the date hereof and (c) 14,334 RSUs granted on July 22, 2019 and unvested as of the date hereof; and (iii) 115,754 shares of Common Stock owned by the Reporting Person.